Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cell Cycle

• Publication date

  2017-07-19

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/15384101.2017.1339848PMID 28723234PMCID PMC5553395
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UniProt: the universal protein knowledgebase

  2016cited by this paper
• Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

  2016cited by this paper
• Designer interface peptide grafts target estrogen receptor alpha dimerization.

  2016cited by this paper
• Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.

  2013cited by this paper
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

  2013cited by this paper
• Ligand-binding dynamics rewire cellular signaling via Estrogen Receptor-α

  2013cited by this paper
• Identification of Estrogen Receptor Dimer Selective Ligands Reveals Growth-Inhibitory Effects on Cells That Co-Express ERα and ERβ

  2012cited by this paper
• ChemMine tools: an online service for analyzing and clustering small molecules

  2011cited by this paper
• Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).

  2010cited by this paper
• Coupling of Receptor Conformation and Ligand Orientation Determine Graded Activity

  2010influential reference
• Identification and characterization of a novel estrogenic ligand actinopolymorphol A.

  2010cited by this paper
• Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions

  2008cited by this paper
• Pathways to tamoxifen resistance.

  2007cited by this paper
• Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes.

  2005cited by this paper
• Integration of the extranuclear and nuclear actions of estrogen.

  2005cited by this paper
• UniProt: the Universal Protein knowledgebase

  2004cited by this paper
• Action of “pure” antiestrogens in inhibiting estrogen receptor action

  2004cited by this paper
• Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice

  2004cited by this paper
• The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

  2004cited by this paper
• Genomic targets of nuclear estrogen receptors.

  2004cited by this paper
• The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo *

  2003cited by this paper
• Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.

  2003cited by this paper
• Tamoxifen: a most unlikely pioneering medicine

  2003cited by this paper
• Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements.

  2002cited by this paper
• Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

  2002cited by this paper
• The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators*

  2001cited by this paper
• Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.

  2001cited by this paper
• Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements.

  2000cited by this paper
• Ligand-, Cell-, and Estrogen Receptor Subtype (α/β)-dependent Activation at GC-rich (Sp1) Promoter Elements*

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.

  2000cited by this paper
• Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.

  1999cited by this paper
• Comparative analyses of mechanistic differences among antiestrogens.

  1999cited by this paper
• Peptide antagonists of the human estrogen receptor.

  1999cited by this paper
• Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140.

  1999cited by this paper
• The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.

  1998cited by this paper
• A new actor in the estrogen receptor drama--enter ER-beta.

  1997cited by this paper
• (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.

  1997cited by this paper
• Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer

  1997cited by this paper
• Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.

  1997cited by this paper
• Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta.

  1997cited by this paper
• MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

  1997cited by this paper
• The novel estrogen receptor‐β subtype: potential role in the cell‐ and promoter‐specific actions of estrogens and anti‐estrogens

  1997cited by this paper
• Editorial: A New Actor in the Estrogen Receptor Drama—Enter ER- (cid:98)

  1997cited by this paper
• Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.

  1997cited by this paper
• Interaction of steroid hormone receptors with the transcription initiation complex.

  1996cited by this paper
• RIP-140 interacts with multiple nuclear receptors by means of two distinct sites

  1996cited by this paper
• ER beta: identification and characterization of a novel human estrogen receptor.

  1996cited by this paper
• ERβ: Identification and characterization of a novel human estrogen receptor

  1996cited by this paper
• Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1.

  1996cited by this paper
• Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.

  1995cited by this paper
• Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

  1995cited by this paper
• Interaction of proteins with transcriptionally active estrogen receptors.

  1994cited by this paper
• Anti‐proliferative and anti‐estrogenic effects of ICI 164,384 and ICI 182,780 in 4‐OH‐tamoxifen‐resistant human breast‐cancer cells

  1994cited by this paper
• Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780

  1993cited by this paper
• MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.

  1993cited by this paper
• Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

  1991cited by this paper
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper
• TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.

  1990cited by this paper
• Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats.

  1988cited by this paper
• Genomic organization of the human oestrogen receptor gene.

  1988cited by this paper
• A new triphenylethylene compound, Fc-1157a

  1986cited by this paper
• No loss of estrogenic or anti‐estrogenic activity after demethylation of droloxifene (3‐OH‐Tamoxifen)

  1985cited by this paper
• Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.

  1983cited by this paper
• Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt.

  1979cited by this paper
• A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol.

  1958cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Human Estrogen Receptor �-Gene Structure, Chromosomal Localization, and Expression Pattern*

  year unknowncited by this paper
• Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank

  year unknowncited by this paper

• Investigating the therapeutic potential of hesperidin targeting CRISP2 in intervertebral disc degeneration and cancer risk mitigation

  2024cites this paper
• ER and PGR Targeting Ability of Phytocompounds Derived from Centella asiatica and Andrographis paniculata: An In-silico Approach

  2022cites this paper
• Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.

  2018cites this paper